Although anti-TNF therapies have improved cardiac function in several experimental animal models [7], large-scale, randomized, placebo-controlled clinical trials of TNF-α antagonists for the treatment of HF were abandoned early due to failed improvement of clinical status and mortality [8,9], and in some studies, the treatment even deteriorated HF [10,11]. This evidence concerns the gene TNF and hydrops fetalis.